Prevalence of adrenal rest tumors and course of gonadal dysfunction in a clinical sample of men with congenital adrenal hyperplasia - a longitudinal analysis over 10 years.

IF 5.3 1区 医学 Q1 ENDOCRINOLOGY & METABOLISM
Matthias K Auer, Duygu Büyükerzurmulu, Christian Lottspeich, Martin Bidlingmaier, Eva Rieger, Hanna Nowotny, Lea Tschaidse, Richard J Auchus, Nicole Reisch
{"title":"Prevalence of adrenal rest tumors and course of gonadal dysfunction in a clinical sample of men with congenital adrenal hyperplasia - a longitudinal analysis over 10 years.","authors":"Matthias K Auer, Duygu Büyükerzurmulu, Christian Lottspeich, Martin Bidlingmaier, Eva Rieger, Hanna Nowotny, Lea Tschaidse, Richard J Auchus, Nicole Reisch","doi":"10.1093/ejendo/lvae112","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Subfertility is prevalent in men with classic 21-hydroxylase deficiency (21OHD). We sought to characterize the long-term evolution of their gonadal function.</p><p><strong>Methods: </strong>Retrospective longitudinal single-center study in 27 men (11 with testicular adrenal rest tissue (TART)); median observation period 12 years; testosterone (T), 11-oxygenated androgens, gonadotropins and inhibin B measurement at each timepoint.</p><p><strong>Results: </strong>T concentrations were below the normal range (n.s.) in 43.2% (no TART) and 54.6% (TART) per patient. After accounting for BMI, sex hormone-binding globulin, and age, men with TART exhibited higher T (14.0 ± 0.80 nmol/l) than those without (11.9 ± 0.71 nmol/l). During the observation period, T levels rose in both groups but more in men with TART (from 10.1 ± 1.1 to 17.3 ± 1.9 nmol/l vs. 10.3 ± 1.0 to 12.8± 1.9 nmol/l); this was accompanied by rising luteinizing hormone and diminishing hydrocortisone equivalent dosages (TART: from 38.1± 3.2 to 35.1 ± 1.8 mg/d; vs. no TART: 28.8 ± 2.7 to 28.1 ± 1.6 mg/d) without correlation with any markers of adrenal androgen control. Inhibin B declined in men with large TART over time while TART status remained stable.</p><p><strong>Conclusion: </strong>T levels below the normal range are frequent in men with 21OHD, regardless of TART, but change little over time. Besides adrenal androgen control gonadal axis suppression from supraphysiological glucocorticoid dosages needs to be considered. While our results do not endorse regular screening for alterations in TART status among adults, Sertoli cell function should be monitored in men with large TART.</p>","PeriodicalId":11884,"journal":{"name":"European Journal of Endocrinology","volume":null,"pages":null},"PeriodicalIF":5.3000,"publicationDate":"2024-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Endocrinology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/ejendo/lvae112","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Subfertility is prevalent in men with classic 21-hydroxylase deficiency (21OHD). We sought to characterize the long-term evolution of their gonadal function.

Methods: Retrospective longitudinal single-center study in 27 men (11 with testicular adrenal rest tissue (TART)); median observation period 12 years; testosterone (T), 11-oxygenated androgens, gonadotropins and inhibin B measurement at each timepoint.

Results: T concentrations were below the normal range (n.s.) in 43.2% (no TART) and 54.6% (TART) per patient. After accounting for BMI, sex hormone-binding globulin, and age, men with TART exhibited higher T (14.0 ± 0.80 nmol/l) than those without (11.9 ± 0.71 nmol/l). During the observation period, T levels rose in both groups but more in men with TART (from 10.1 ± 1.1 to 17.3 ± 1.9 nmol/l vs. 10.3 ± 1.0 to 12.8± 1.9 nmol/l); this was accompanied by rising luteinizing hormone and diminishing hydrocortisone equivalent dosages (TART: from 38.1± 3.2 to 35.1 ± 1.8 mg/d; vs. no TART: 28.8 ± 2.7 to 28.1 ± 1.6 mg/d) without correlation with any markers of adrenal androgen control. Inhibin B declined in men with large TART over time while TART status remained stable.

Conclusion: T levels below the normal range are frequent in men with 21OHD, regardless of TART, but change little over time. Besides adrenal androgen control gonadal axis suppression from supraphysiological glucocorticoid dosages needs to be considered. While our results do not endorse regular screening for alterations in TART status among adults, Sertoli cell function should be monitored in men with large TART.

先天性肾上腺皮质增生症男性临床样本中肾上腺休止期肿瘤的患病率和性腺功能障碍的病程--10 年纵向分析。
背景:典型的21-羟化酶缺乏症(21OHD)男性普遍存在不育症。我们试图了解他们性腺功能长期演变的特点:方法:对27名男性(11名患有睾丸肾上腺休息组织(TART))进行回顾性纵向单中心研究;中位观察期12年;在每个时间点测量睾酮(T)、11-氧合雄激素、促性腺激素和抑制素B:43.2%(无 TART)和 54.6%(有 TART)的患者睾酮浓度低于正常范围(n.s.)。在考虑体重指数、性激素结合球蛋白和年龄因素后,TART 患者的 T(14.0 ± 0.80 nmol/l)高于无 TART 患者(11.9 ± 0.71 nmol/l)。在观察期间,两组男性的 T 水平都有所上升,但 TART 患者的 T 水平上升幅度更大(从 10.1 ± 1.1 nmol/l 升至 17.3 ± 1.9 nmol/l 与 10.3 ± 1.0 nmol/l 升至 12.8 ± 1.9 nmol/l);与此同时,黄体生成素上升,氢化可的松当量剂量减少(TART:从 38.1± 3.2 mg/d 降至 35.1± 1.8 mg/d;与无 TART 相比:从 28.8± 2.7 mg/d 降至 28.1± 1.6 mg/d),但与肾上腺雄激素控制的任何指标均无相关性。随着时间的推移,大TART男性的抑制素B下降,而TART状态保持稳定:患有21OHD的男性体内T水平经常低于正常范围,与TART无关,但随着时间的推移变化不大。除了肾上腺雄激素控制外,还需要考虑超生理糖皮质激素剂量对性腺轴的抑制。虽然我们的研究结果并不支持对成年人的TART状态变化进行定期筛查,但对于TART较大的男性,应监测其Sertoli细胞功能。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
European Journal of Endocrinology
European Journal of Endocrinology 医学-内分泌学与代谢
CiteScore
9.80
自引率
3.40%
发文量
354
审稿时长
1 months
期刊介绍: European Journal of Endocrinology is the official journal of the European Society of Endocrinology. Its predecessor journal is Acta Endocrinologica. The journal publishes high-quality original clinical and translational research papers and reviews in paediatric and adult endocrinology, as well as clinical practice guidelines, position statements and debates. Case reports will only be considered if they represent exceptional insights or advances in clinical endocrinology. Topics covered include, but are not limited to, Adrenal and Steroid, Bone and Mineral Metabolism, Hormones and Cancer, Pituitary and Hypothalamus, Thyroid and Reproduction. In the field of Diabetes, Obesity and Metabolism we welcome manuscripts addressing endocrine mechanisms of disease and its complications, management of obesity/diabetes in the context of other endocrine conditions, or aspects of complex disease management. Reports may encompass natural history studies, mechanistic studies, or clinical trials. Equal consideration is given to all manuscripts in English from any country.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信